Should I buy or sell SAB Biotherapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SABS shares. View SABS analyst ratings or view top-rated stocks .

What is SAB Biotherapeutics' stock price target for 2024?

2 brokerages have issued twelve-month price targets for SAB Biotherapeutics' shares. Their SABS share price targets range from $1.00 to $1.00. On average, they expect the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 9.9% from the stock's current price. View analysts price targets for SABS or view top-rated stocks among Wall Street analysts .

How have SABS shares performed in 2023?

SAB Biotherapeutics' stock was trading at $0.5899 on January 1st, 2023. Since then, SABS shares have increased by 54.3% and is now trading at $0.91. View the best growth stocks for 2023 here .

When is SAB Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our SABS earnings forecast .

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its quarterly earnings results on Monday, November, 13th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). The firm had revenue of $1.27 million for the quarter. SAB Biotherapeutics had a negative net margin of 664.68% and a negative trailing twelve-month return on equity of 120.36%.

Who are SAB Biotherapeutics' major shareholders?

SAB Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pathstone Family Office LLC (0.97%). Insiders that own company stock include Christine E Hamilton, Michael King and Samuel J Reich. View institutional ownership trends .

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

SAB Biotherapeutics Stock Price, News & Analysis (NASDAQ:SABS)

$0.91

-0.03 (-3.19%)

(As of 12/4/2023 ET)

Compare

Today's Range: $0.88
▼
$0.97
50-Day Range: $0.47
▼
$1.01
52-Week Range: $0.37
▼
$1.45

Volume: 197,478 shs
Average Volume: 408,146 shs
Market Capitalization: $47.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.00

SAB Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 9.9% Upside
$1.00 Price Target
Short Interest: Healthy
0.61% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$14,290 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.46) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

865th out of 952 stocks

Biological Products, Except Diagnostic Industry

144th out of 155 stocks

1.3

Analyst's Opinion

Consensus Rating
SAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.00, SAB Biotherapeutics has a forecasted upside of 9.9% from its current price of $0.91.
Amount of Analyst Coverage
SAB Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
0.61% of the float of SAB Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
SAB Biotherapeutics has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in SAB Biotherapeutics has recently decreased by 12.09%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
SAB Biotherapeutics does not currently pay a dividend.
Dividend Growth
SAB Biotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SABS.

3.1

News and Social Media Coverage

News Sentiment
SAB Biotherapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for SAB Biotherapeutics this week, compared to 1 article on an average week.
Search Interest
4 people have searched for SABS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
2 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SAB Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $14,290.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
31.18% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.82% of the stock of SAB Biotherapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($0.46) to ($0.30) per share.
Price to Book Value per Share Ratio
SAB Biotherapeutics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SAB Biotherapeutics Stock (NASDAQ:SABS)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SABS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SABS Stock News Headlines

December 1, 2023 | msn.com

VerifyMe And 3 Other Stocks Under $2 Insiders Are Buying

November 29, 2023 | finance.yahoo.com

SAB Biotherapeutics Starts Human Clinical Trial of Diabetes Treatment

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 29, 2023 | msn.com

EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia

November 29, 2023 | finance.yahoo.com

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

November 20, 2023 | finanznachrichten.de

SAB Biotherapeutics, Inc.: SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

November 20, 2023 | finance.yahoo.com

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

November 14, 2023 | finanznachrichten.de

SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 14, 2023 | msn.com

SAB Biotherapeutics GAAP EPS of -$0.10

November 14, 2023 | finance.yahoo.com

SAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in Financing

November 14, 2023 | finance.yahoo.com

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

November 14, 2023 | finance.yahoo.com

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

November 9, 2023 | finance.yahoo.com

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

November 6, 2023 | msn.com

SAB Biotherapeutics files to sell 412.7M units to noteholders

October 24, 2023 | finance.yahoo.com

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

October 19, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: SAB Biotherapeutics (SABS), Elevance Health (ELV)

October 19, 2023 | finance.yahoo.com

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

October 6, 2023 | markets.businessinsider.com

SAB Biotherapeutics’ Financial Stability and Potential Growth: A Comprehensive Analysis of Edward White’s Buy Rating

October 6, 2023 | markets.businessinsider.com

Secured Financing and Promising Clinical Developments Bolster Buy Rating for SAB Biotherapeutics

October 5, 2023 | finance.yahoo.com

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

October 5, 2023 | finance.yahoo.com

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

October 3, 2023 | finance.yahoo.com

SAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes Treatment

October 2, 2023 | finance.yahoo.com

EXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidate

October 2, 2023 | finance.yahoo.com

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

August 22, 2023 | seekingalpha.com

SAB Biotherapeutics GAAP EPS of -$0.14

August 22, 2023 | markets.businessinsider.com

SAB Biotherapeutics (SABS) Gets a Buy from Chardan Capital

See More Headlines

Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/12/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:SABS
CUSIP: N/A
CIK: 1833214
Web: www.bigcypressaccorp.com
Phone: 605-679-6980
Fax: N/A
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.00
High Stock Price Target: $1.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +9.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,740,000.00
Net Margins: -664.68%
Pretax Margin: -664.04%
Return on Equity: -120.36%
Return on Assets: -69.17%

Debt

Debt-to-Equity Ratio: 0.23
Current Ratio: 0.34
Quick Ratio: 0.34

Sales & Book Value

Annual Sales: $23.90 million
Price / Sales: 1.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.72 per share
Price / Book: 1.26

Miscellaneous

Outstanding Shares: 52,320,000
Free Float: 36,006,000
Market Cap: $47.61 million
Optionable: Not Optionable
Beta: 1.03

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Samuel J. Reich (Age 48)
Executive Chairman
Comp: $376.2k
Dr. Eddie Joe Sullivan Ph.D. (Age 57)
Co-Founder, President, CEO & Director
Comp: $430.62k
Ms. Christine E. Hamilton M.B.A. (Age 67)
Co-Founder & Independent Director
Comp: $25k
Dr. Alexandra Kropotova M.B.A. (Age 50)
M.D., Executive VP & Chief Medical Officer
Comp: $486.96k
Dr. Edward D. Hamilton D.V.M.
Co-Founder & Board Observer
Mr. Michael George King Jr. (Age 62)
Chief Financial Officer
Dr. Christoph Bausch M.B.A. (Age 52)
Ph.D., Executive VP & COO
Mr. Russell P. Beyer C.M.A. (Age 68)
M.B.A., Senior Advisor
Dr. Carlos N. Carillo Ph.D.
Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SABS Stock Analysis - Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SABS shares.
View SABS analyst ratings or view top-rated stocks.
What is SAB Biotherapeutics' stock price target for 2024?: 2 brokerages have issued twelve-month price targets for SAB Biotherapeutics' shares. Their SABS share price targets range from $1.00 to $1.00. On average, they expect the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 9.9% from the stock's current price.
View analysts price targets for SABS or view top-rated stocks among Wall Street analysts.
How have SABS shares performed in 2023?: SAB Biotherapeutics' stock was trading at $0.5899 on January 1st, 2023. Since then, SABS shares have increased by 54.3% and is now trading at $0.91.
View the best growth stocks for 2023 here.
When is SAB Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our SABS earnings forecast.

How were SAB Biotherapeutics' earnings last quarter?: SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its quarterly earnings results on Monday, November, 13th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). The firm had revenue of $1.27 million for the quarter. SAB Biotherapeutics had a negative net margin of 664.68% and a negative trailing twelve-month return on equity of 120.36%.
Who are SAB Biotherapeutics' major shareholders?: SAB Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pathstone Family Office LLC (0.97%). Insiders that own company stock include Christine E Hamilton, Michael King and Samuel J Reich.
View institutional ownership trends.
How do I buy shares of SAB Biotherapeutics?: Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SABS) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

SAB Biotherapeutics Stock Price, News & Analysis (NASDAQ:SABS)

SAB Biotherapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About SAB Biotherapeutics Stock (NASDAQ:SABS)

SABS Stock Price History

SABS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SABS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™